Avidity Reports Over 50% Reduction In DUX4 Regulated Genes In Phase 1/2 FORTITUDE Trial For Facioscapulohumeral Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences reported over 50% reduction in DUX4 regulated genes in its Phase 1/2 FORTITUDE trial for facioscapulohumeral muscular dystrophy (FSHD). The company plans to accelerate the initiation of registrational cohorts. The investigational therapy, delpacibart braxlosiran (AOC 1020), showed promising results in muscle strength and patient outcomes, with favorable safety and tolerability.
June 12, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity Biosciences reported significant progress in its Phase 1/2 FORTITUDE trial for FSHD, showing over 50% reduction in DUX4 regulated genes and positive trends in muscle strength and patient outcomes. The company plans to accelerate the initiation of registrational cohorts, indicating confidence in the therapy's potential.
The significant reduction in DUX4 regulated genes and positive trends in muscle strength and patient outcomes are strong indicators of the therapy's potential. The decision to accelerate registrational cohorts suggests confidence in the trial results, likely boosting investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100